Successful treatment of metastatic colorectal cancer with apatinib: report of two cases and literature review
Apatinib, a novel small molecule tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor-2, was approved for metastatic gastric adenocarcinoma in China in Oct 2014. This is the first report on its use for advanced colorectal cancer as a kind of third-line therapy to date....
Saved in:
Published in | OncoTargets and therapy Vol. 11; pp. 883 - 890 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
New Zealand
Dove Medical Press Limited
01.01.2018
Taylor & Francis Ltd Dove Medical Press |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Apatinib, a novel small molecule tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor-2, was approved for metastatic gastric adenocarcinoma in China in Oct 2014. This is the first report on its use for advanced colorectal cancer as a kind of third-line therapy to date. Here we report two Chinese patients who presented with metastatic colorectal cancer who received apatinib 850 mg daily as a third-line therapy. Both the patients achieved favorable benefits in outcomes after the administration of apatinib. Patient 1 benefited 4 months progression-free survival and 11 months overall survival, while patient 2's progression-free survival was over 10 months. Both the patients presented hand-foot syndrome, and one of them suffered a slight impairment of liver function, mild elevated blood pressure, and proteinuria. But these adverse events were manageable with symptomatic treatment and dose reduction or a short-time drug withdrawal. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work |
ISSN: | 1178-6930 1178-6930 |
DOI: | 10.2147/OTT.S148412 |